Research location

New Haven

Connecticut, United States

Published trials1,930

Site observations2,130

Linked trials published1,930

Page1 / 39

Research activity in New Haven

Connecticut, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 1,930 trials and 2,130 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in New Haven

1,930 linked trials · page 1 of 39

Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 DiabetesNCT07864168 · 2026-10-01 · 1 site observation

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm InfantsNCT06373289 · 2026-09-22 · 1 site observation

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941 · 2026-09-17 · 1 site observation

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2026-08-26 · 1 site observation

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart DiseaseNCT07214376 · 2026-08-21 · 1 site observation

Rash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15 · 1 site observation

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · 2026-08-04 · 1 site observation

Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGNCT07216391 · 2026-07-29 · 1 site observation

A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's MedicationsNCT07330258 · 2026-07-21 · 1 site observation

The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseNCT07610369 · 2026-07-10 · 1 site observation

Promoting Palliative Care for People With Heart FailureNCT06933875 · 2026-07-02 · 2 site observations

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedNCT07650916 · 2026-06-25 · 1 site observation

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate AsthmaNCT07660731 · 2026-06-17 · 1 site observation

Statins to Prevent Cancer Associated Blood ClotsNCT07303816 · 2026-06-11 · 1 site observation

Evaluation of a Mobile App Program for Coping With CancerNCT06923501 · 2026-06-11 · 1 site observation

Music for Pain and DementiaNCT07602283 · 2026-06-09 · 1 site observation

Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of LifeNCT07376655 · 2026-06-04 · 1 site observation

RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entryNCT07136363 · 2026-06-01 · 1 site observation

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerNCT07604571 · 2026-05-28 · 1 site observation

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy VolunteersNCT07617688 · 2026-05-27 · 1 site observation

A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571 · 2026-05-21 · 1 site observation

Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes MellitusNCT07142252 · 2026-05-14 · 1 site observation

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 SystemNCT07579702 · 2026-05-13 · 1 site observation

Evaluation of [¹⁸F]MODAG-009 PET Imaging in SynucleinopathiesNCT07640555 · 2026-05-13 · 1 site observation

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNCT07214532 · 2026-05-08 · 1 site observation

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)NCT07513376 · 2026-05-04 · 1 site observation

A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast CancerNCT07524855 · 2026-04-09 · 1 site observation

Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655 · 2026-04-08 · 4 site observations

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsNCT07424404 · 2026-04-07 · 1 site observation

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation

Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health ClinicsNCT06684613 · 2026-03-11 · 1 site observation

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 DiabetesNCT07061574 · 2026-03-10 · 1 site observation

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal SyndromeNCT07273838 · 2026-03-05 · 2 site observations

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498 · 2026-02-22 · 1 site observation

Evolutionary Clinical Trial for Novel Biomarker-Driven TherapiesNCT07340541 · 2026-02-16 · 1 site observation

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsNCT07360314 · 2026-02-13 · 1 site observation

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 1 site observation

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation

A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation

A Study of Brenipatide in Adult Participants With Major Depressive DisorderNCT07412756 · 2026-02-09 · 1 site observation

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 DiabetesNCT07224321 · 2026-02-04 · 1 site observation

Digital Mindfulness for Young Adults With Type 1 DiabetesNCT07062887 · 2026-02-04 · 1 site observation

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate CancerNCT07258407 · 2026-01-30 · 1 site observation

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic AsthmaNCT07323654 · 2026-01-28 · 1 site observation

Iadademstat + SBRT With Atezo in ES-SCLCNCT07113691 · 2026-01-20 · 1 site observation

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseaseNCT07271186 · 2026-01-09 · 1 site observation

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsNCT07349537 · 2026-01-08 · 1 site observation

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsNCT07361562 · 2025-12-30 · 1 site observation

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.